Duchenne muscular dystrophy (DMD) is a devastating genetic condition that results in progressive muscle weakness, spinal deformities, heart failure and early mortality. While genetic therapies are being explored, current treatments only alleviate symptoms. However, MCW’s Dr. Brian Lin and his lab are researching a promising approach that examines a calcium channel which becomes hyperactive in DMD and how inhibiting that channel could counteract the leading cause of death in DMD patients. Learn m

52K views · 510 reactions | Today, the Food and Drug Administration approved the first gene therapy treatment for Duchenne Muscular Dystrophy. This groundbreaking treatment, developed here at Nationwide Children’s, is giving boys like Easton and Connor a future full of hope and possibilities. Watch their incredible stories. Learn more: https://bit.ly/3PzvLQK | Nationwide Children's Hospital | Facebook